Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

E1018

Phase 1Small molecule

E1018 is one of 28 small molecule programs targeting Malaria. It is currently in Phase 1.

1

Indications

1

Total Trials

1

Active Trials

27

Competitors

Pipeline

Status by Indication[3][1]

Indication

MalariaActive, not recruiting

MalariaPhase 1

Active, not recruiting

Competition

Competitive Landscape

94 competitors in Malaria

#DrugCompanyPhaseTrials

Dihydroartemisinin-Piperaquine

Rabies Vaccine

YF-Vax

Krintafel

GGlaxo Dba Glaxosmithkline

Artemether-Lumefantrine (AL)

Artesunate-Amodiaquine

Pfspz Challenge

R21/matrix-M

UUniversity of Oxford

Pyramax

SShin Poong Pharmaceutical Co. Ltd.

Biltricide

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Active, not recruiting

Malaria

NCT06854042

Clinical

Trials by Indication[1]

Malaria1 trial

A First-In-Human, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral E1018 in Healthy Adult Subjects

Active, not recruiting· Eisai logo

Eisai·Phase 1·NCT06854042·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for E1018. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — E1018 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for E1018. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eisai company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Eisai

Related News